- Home
- BTAI vs MBIO Comparison
BTAI vs MBIO Comparison
Compare BTAI & MBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BTAI
- MBIO
- Stock Information
- Founded
- BTAI 2017
- MBIO 2015
- Country
- BTAI United States
- MBIO United States
- Employees
- BTAI N/A
- MBIO N/A
- Industry
- BTAI Biotechnology: Pharmaceutical Preparations
- MBIO Biotechnology: Pharmaceutical Preparations
- Sector
- BTAI Health Care
- MBIO Health Care
- Exchange
- BTAI Nasdaq
- MBIO Nasdaq
- Market Cap
- BTAI 7.2M
- MBIO 7.3M
- IPO Year
- BTAI 2018
- MBIO N/A
- Fundamental
- Price
- BTAI $1.88
- MBIO $1.29
- Analyst Decision
- BTAI Buy
- MBIO Strong Buy
- Analyst Count
- BTAI 5
- MBIO 1
- Target Price
- BTAI $42.60
- MBIO $100.00
- AVG Volume (30 Days)
- BTAI 1.2M
- MBIO 62.4K
- Earning Date
- BTAI 03-27-2025
- MBIO 05-14-2025
- Dividend Yield
- BTAI N/A
- MBIO N/A
- EPS Growth
- BTAI N/A
- MBIO N/A
- EPS
- BTAI N/A
- MBIO N/A
- Revenue
- BTAI $2,266,000.00
- MBIO N/A
- Revenue This Year
- BTAI $105.36
- MBIO N/A
- Revenue Next Year
- BTAI $46.93
- MBIO N/A
- P/E Ratio
- BTAI N/A
- MBIO N/A
- Revenue Growth
- BTAI 64.20
- MBIO N/A
- 52 Week Low
- BTAI $1.72
- MBIO $1.20
- 52 Week High
- BTAI $49.58
- MBIO $65.00
- Technical
- Relative Strength Index (RSI)
- BTAI 39.27
- MBIO 22.04
- Support Level
- BTAI $1.76
- MBIO $1.36
- Resistance Level
- BTAI $2.37
- MBIO $1.51
- Average True Range (ATR)
- BTAI 0.28
- MBIO 0.11
- MACD
- BTAI 0.03
- MBIO 0.11
- Stochastic Oscillator
- BTAI 16.95
- MBIO 1.52
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
About MBIO Mustang Bio Inc.
Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapy into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.